Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* a diagnosis of myofascial pain according to the research diagnostic criteria for TMD Axis I (RDC/TMD)~* duration of TMD pain ≥ 3 months~* self-assessed average myofascial-TMD pain intensity of ≥ 30 mm on a 100-mm visual analogue scale (VAS) during one week prior to examination~* familiar pain upon digital palpation of the masseter and/or the temporalis muscles.~* The patients remain included with one or several co-diagnoses of; a) disc displacement with or without reduction, b) osteoarthrosis in the any of the temporomandibular joints (TMJ), and c) episodic or chronic tension type headache~Exclusion Criteria:~* diagnosed systemic muscular or joint diseases (e.g. fibromyalgia, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis)~* whiplash associated disorder~* neuropathic pain or neurological disorders (e.g. myasthenia gravis, orofacial dystonia)~* history of psychiatric disorders~* pain of dental origin~* use of muscle relaxants or any medication that might influence the response to pain~* pregnancy or lactation~* known hypersensitivity to granisetron

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Granisetron (Type: EXPERIMENTAL): Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
- Control (placebo) (Type: PLACEBO_COMPARATOR): Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).